Jagsonpal Pharmaceuticals Limited — Investor Meet, 06-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year.

FY25 revenue rose 28.8% YoY to ₹268.7 Cr, with operating EBITDA up 410 bps to 21.5% (₹57.9 Cr) and PAT growing 66.7% to ₹37.5 Cr. Q4 revenue surged 34.7% to ₹58.6 Cr, EBITDA nearly doubled to ₹9.7 Cr. Indocap® sales crossed ₹50 Cr. Management highlighted cost discipline, successful acquisition integration, and a focus on organic and selective inorganic growth, especially in dermatology, pediatrics, orthopedics, and gynecology. Strong cash and balance sheet support future investments.